Stiff person syndrome (SPS) is a rare autoimmune neurological disorder that causes muscle stiffness in the torso, arms, and legs, which can make movement difficult. Around 80% of patients experience significant loss of mobility, often requiring walking aids or a wheelchair, and the condition carries a risk of permanent disability and increased mortality.
Currently, there are no therapies specifically approved by the FDA for SPS, and so treatment focuses on managing symptoms and improving quality of life. This typically involves a combination of medications to reduce stiffness and spasms, immunotherapies to address the underlying autoimmune process, and supportive care such as physical and occupational therapy to maintain function and independence.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.